Page last updated: 2024-11-12
arachidin-1
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
arachidin-1: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 11220670 |
| CHEMBL ID | 2230262 |
| SCHEMBL ID | 18268151 |
| MeSH ID | M0511148 |
Synonyms (14)
| Synonym |
|---|
| arachidin-1 |
| 5-[(e)-2-(3,4-dihydroxyphenyl)ethenyl]-2-[(e)-3-methylbut-1-enyl]benzene-1,3-diol |
| CHEMBL2230262 |
| arachidin i |
| SCHEMBL18268151 |
| arachidin 1 |
| 4-((1e)-2-(3,5-dihydroxy-4-((1e)-3-methyl-1-buten-1-yl)phenyl)ethenyl)-1,2-benzenediol |
| 98391-38-9 |
| 5-((e)-2-(3,4-dihydroxyphenyl)vinyl)-2-((e)-3-methylbut-1-enyl)benzene-1,3-diol |
| arachidin-i |
| 48JFB58T4V , |
| unii-48jfb58t4v |
| arachidin i- |
| 1,2-benzenediol, 4-((1e)-2-(3,5-dihydroxy-4-((1e)-3-methyl-1-buten-1-yl)phenyl)ethenyl)- |
Research Excerpts
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| "The therapeutic promise of trans-resveratrol (tRes) is limited by poor bioavailability following rapid metabolism." | ( Natural prenylated resveratrol analogs arachidin-1 and -3 demonstrate improved glucuronidation profiles and have affinity for cannabinoid receptors. Bratton, SM; Brents, LK; Doerksen, RJ; Liu, H; Medina-Bolivar, F; Nair, V; Nopo-Olazabal, L; Patel, RY; Prather, PL; Radominska-Pandya, A; Seely, KA, 2012) | 0.65 |
| "Prenylated stilbenoids may be preferable alternatives to tRes due to increased bioavailability via slowed metabolism." | ( Natural prenylated resveratrol analogs arachidin-1 and -3 demonstrate improved glucuronidation profiles and have affinity for cannabinoid receptors. Bratton, SM; Brents, LK; Doerksen, RJ; Liu, H; Medina-Bolivar, F; Nair, V; Nopo-Olazabal, L; Patel, RY; Prather, PL; Radominska-Pandya, A; Seely, KA, 2012) | 0.65 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (5)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1081911 | Antifungal activity against Botryotinia fuckeliana assessed as growth inhibition after 72 hr by NCCLS M27-A broth microdilution method | 2011 | Journal of agricultural and food chemistry, Mar-09, Volume: 59, Issue:5 | Biological activity of peanut (Arachis hypogaea) phytoalexins and selected natural and synthetic Stilbenoids. |
| AID1081912 | Antifungal activity against Botryotinia fuckeliana assessed as growth inhibition after 48 hr by NCCLS M27-A broth microdilution method | 2011 | Journal of agricultural and food chemistry, Mar-09, Volume: 59, Issue:5 | Biological activity of peanut (Arachis hypogaea) phytoalexins and selected natural and synthetic Stilbenoids. |
| AID1081919 | Octanol-water partition coefficient, log P of the compound by HPLC analysis | 2011 | Journal of agricultural and food chemistry, Mar-09, Volume: 59, Issue:5 | Biological activity of peanut (Arachis hypogaea) phytoalexins and selected natural and synthetic Stilbenoids. |
| AID1081914 | Antifungal activity against Phomopsis obscurans assessed as growth inhibition after 144 hr by NCCLS M27-A broth microdilution method | 2011 | Journal of agricultural and food chemistry, Mar-09, Volume: 59, Issue:5 | Biological activity of peanut (Arachis hypogaea) phytoalexins and selected natural and synthetic Stilbenoids. |
| AID1081913 | Antifungal activity against Phomopsis obscurans assessed as growth inhibition after 120 hr by NCCLS M27-A broth microdilution method | 2011 | Journal of agricultural and food chemistry, Mar-09, Volume: 59, Issue:5 | Biological activity of peanut (Arachis hypogaea) phytoalexins and selected natural and synthetic Stilbenoids. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (15)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (6.67) | 29.6817 |
| 2010's | 10 (66.67) | 24.3611 |
| 2020's | 4 (26.67) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.14
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.14) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 16 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||